{"id":"https://openalex.org/W3081631915","doi":"https://doi.org/10.1111/jvh.13395","title":"Real\u2010world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan","display_name":"Real\u2010world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan","publication_year":2020,"publication_date":"2020-09-01","ids":{"openalex":"https://openalex.org/W3081631915","doi":"https://doi.org/10.1111/jvh.13395","mag":"3081631915","pmid":"https://pubmed.ncbi.nlm.nih.gov/32869924"},"language":"en","primary_location":{"id":"doi:10.1111/jvh.13395","doi":"https://doi.org/10.1111/jvh.13395","is_oa":false,"landing_page_url":"https://doi.org/10.1111/jvh.13395","pdf_url":null,"source":{"id":"https://openalex.org/S164225461","display_name":"Journal of Viral Hepatitis","issn_l":"1352-0504","issn":["1352-0504","1365-2893"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Viral Hepatitis","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111846512","display_name":"Masashi Mizokami","orcid":"https://orcid.org/0000-0001-5269-4006","observed_orcids":["https://orcid.org/0000-0001-5269-4006"]},"institutions":[{"id":"https://openalex.org/I4210094012","display_name":"National Center for Global Health and Medicine","ror":"https://ror.org/00r9w3j27","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210094012"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masashi Mizokami","raw_affiliation_strings":["National Center for Global Health and Medicine, Ichikawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Center for Global Health and Medicine, Ichikawa, Japan","institution_ids":["https://openalex.org/I4210094012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020584668","display_name":"Lauren J. Liu","orcid":"https://orcid.org/0000-0002-1425-9721","observed_orcids":["https://orcid.org/0000-0002-1425-9721"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lauren J. Liu","raw_affiliation_strings":["Gilead Sciences Inc., Foster City, CA, USA"],"raw_orcid":"https://orcid.org/0000-0002-1425-9721","affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Naoto Fujiyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405284944","display_name":"Gilead Sciences (Japan)","ror":"https://ror.org/04getey85","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210140816","https://openalex.org/I4405284944"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naoto Fujiyama","raw_affiliation_strings":["Gilead Sciences K.K., Chiyoda-ku, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences K.K., Chiyoda-ku, Japan","institution_ids":["https://openalex.org/I4405284944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027146598","display_name":"Marcus Littman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcus Littman","raw_affiliation_strings":["Gilead Sciences Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034938550","display_name":"Jason X.\u2010J. Yuan","orcid":"https://orcid.org/0000-0002-0685-4862","observed_orcids":["https://orcid.org/0000-0002-0685-4862"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Yuan","raw_affiliation_strings":["Gilead Sciences Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108365272","display_name":"Tomoko Sekiya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405284944","display_name":"Gilead Sciences (Japan)","ror":"https://ror.org/04getey85","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210140816","https://openalex.org/I4405284944"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Sekiya","raw_affiliation_strings":["Gilead Sciences K.K., Chiyoda-ku, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences K.K., Chiyoda-ku, Japan","institution_ids":["https://openalex.org/I4405284944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022433565","display_name":"Charlotte Hedskog","orcid":"https://orcid.org/0000-0003-0512-7767","observed_orcids":["https://orcid.org/0000-0003-0512-7767"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charlotte Hedskog","raw_affiliation_strings":["Gilead Sciences Inc., Foster City, CA, USA"],"raw_orcid":"https://orcid.org/0000-0003-0512-7767","affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062402842","display_name":"Leslie J. Ng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leslie J. Ng","raw_affiliation_strings":["Gilead Sciences Inc., Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences Inc., Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5020584668"],"corresponding_institution_ids":["https://openalex.org/I4210140816"],"apc_list":{"value":4100,"currency":"USD","value_usd":4100},"apc_paid":null,"fwci":0.6122,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.63371377,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"28","issue":"1","first_page":"129","last_page":"141"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11495","display_name":"Animal Virus Infections Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1103","display_name":"Animal Science and Zoology"},"field":{"id":"https://openalex.org/fields/11","display_name":"Agricultural and Biological Sciences"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ledipasvir-sofosbuvir","display_name":"ledipasvir/sofosbuvir","score":0.984000027179718},{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.9589999914169312},{"id":"https://openalex.org/keywords/hcv-genotype-1","display_name":"HCV genotype 1","score":0.9800000190734863},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.7129999995231628},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8899999856948853},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8740000128746033},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.9639999866485596},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.7450000047683716},{"id":"https://openalex.org/keywords/compensated-cirrhosis","display_name":"compensated cirrhosis","score":0.9649999737739563},{"id":"https://openalex.org/keywords/advanced-fibrosis","display_name":"advanced fibrosis","score":0.8240000009536743},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ns5a-resistance-associated-substitutions","display_name":"NS5A resistance-associated substitutions","score":0.8989999890327454},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7049999833106995}],"concepts":[{"id":"https://openalex.org/C2775999097","wikidata":"https://www.wikidata.org/wiki/Q15409409","display_name":"Ledipasvir","level":5,"score":0.8900880813598633},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8849145174026489},{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.8293142318725586},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7563567161560059},{"id":"https://openalex.org/C2777214474","wikidata":"https://www.wikidata.org/wiki/Q147778","display_name":"Cirrhosis","level":2,"score":0.7151143550872803},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.6805986166000366},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.5998530387878418},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.554840087890625},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.5253695249557495},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.5227944254875183},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.504156231880188},{"id":"https://openalex.org/C2777075537","wikidata":"https://www.wikidata.org/wiki/Q929737","display_name":"Liver disease","level":2,"score":0.44445550441741943},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.1789190173149109},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.15215089917182922},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.11792662739753723},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000069474","descriptor_name":"Sofosbuvir","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000072230","descriptor_name":"Sustained Virologic Response","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005449","descriptor_name":"Fluorenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/jvh.13395","doi":"https://doi.org/10.1111/jvh.13395","is_oa":false,"landing_page_url":"https://doi.org/10.1111/jvh.13395","pdf_url":null,"source":{"id":"https://openalex.org/S164225461","display_name":"Journal of Viral Hepatitis","issn_l":"1352-0504","issn":["1352-0504","1365-2893"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Viral Hepatitis","raw_type":"journal-article"},{"id":"pmid:32869924","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32869924","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of viral hepatitis","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1732930179","https://openalex.org/W1888976023","https://openalex.org/W2066725789","https://openalex.org/W2081897332","https://openalex.org/W2092646281","https://openalex.org/W2100460925","https://openalex.org/W2101598010","https://openalex.org/W2151554611","https://openalex.org/W2155965977","https://openalex.org/W2157294800","https://openalex.org/W2258263090","https://openalex.org/W2363290905","https://openalex.org/W2413213127","https://openalex.org/W2415783139","https://openalex.org/W2463921556","https://openalex.org/W2470344850","https://openalex.org/W2510623134","https://openalex.org/W2512251569","https://openalex.org/W2515985363","https://openalex.org/W2538194643","https://openalex.org/W2558567422","https://openalex.org/W2564813289","https://openalex.org/W2593764560","https://openalex.org/W2609928580","https://openalex.org/W2749229801","https://openalex.org/W2777856481","https://openalex.org/W2784193918","https://openalex.org/W2795863480","https://openalex.org/W2807126090","https://openalex.org/W2883097184","https://openalex.org/W2897919916","https://openalex.org/W2939416704","https://openalex.org/W2958929388","https://openalex.org/W7073973443"],"related_works":["https://openalex.org/W2795863480","https://openalex.org/W2906320704","https://openalex.org/W2890297610","https://openalex.org/W2531545597","https://openalex.org/W2777856481","https://openalex.org/W33114692","https://openalex.org/W1732930179","https://openalex.org/W2609928580","https://openalex.org/W4281715618","https://openalex.org/W2935071140"],"abstract_inverted_index":{"As":[0],"patients":[1,48,80,155,179,216,236],"with":[2,49,67,86,158,217,230,237],"chronic":[3,204],"hepatitis":[4],"C":[5],"virus":[6],"(HCV)":[7],"tend":[8],"to":[9,23,34],"be":[10],"older":[11],"and/or":[12],"have":[13],"advanced":[14,63,186],"liver":[15,205],"disease":[16],"in":[17,42,153,224],"Japan,":[18],"real-world":[19,44,211,232],"data":[20],"are":[21],"needed":[22],"evaluate":[24],"safe":[25],"and":[26,37,56,65,100,105,122,126,132,136,142,148,173,202,245],"effective":[27],"treatment":[28,222,246],"options.":[29],"The":[30],"study":[31,75,213],"aim":[32],"was":[33,76],"assess":[35],"safety":[36,97,243],"effectiveness":[38],"of":[39,46,117,160,214,227,241],"ledipasvir/sofosbuvir":[40],"(LDV/SOF)":[41],"a":[43],"cohort":[45],"Japanese":[47,215],"HCV":[50,83,218],"genotype":[51],"(GT)":[52],"1":[53],"infection":[54,85],"overall":[55,131,171],"by":[57,133],"patient":[58],"subgroups:":[59],"elderly,":[60],"compensated":[61,161,197],"cirrhotic,":[62],"fibrotic":[64,187],"those":[66,157],"hepatocellular":[68],"carcinoma":[69],"(HCC).":[70],"A":[71],"large":[72],"prospective":[73],"observational":[74,212],"conducted,":[77],"enrolling":[78],"adult":[79],"treated":[81],"for":[82,96,106],"GT1":[84,219],"LDV/SOF":[87,221],"at":[88,110],"clinical":[89],"sites":[90],"across":[91,174],"Japan.":[92],"Patients":[93],"were":[94,129,139,169,181],"observed":[95],"outcomes":[98,244],"during":[99],"4":[101],"weeks":[102],"after":[103],"treatment,":[104],"sustained":[107],"virologic":[108],"response":[109],"12-weeks":[111],"post-treatment":[112],"(SVR12).":[113],"Incidence":[114],"rates":[115,128,168],"(IRs)":[116],"adverse":[118,228,242],"drug":[119],"reactions":[120],"(ADRs)":[121],"serious":[123],"ADRs":[124],"(SADRs)":[125],"SVR12":[127,167],"assessed":[130],"subgroups.":[134],"ADR":[135],"SADR":[137],"IRs":[138],"low":[140,225],"(2.26":[141],"0.17":[143],"per":[144],"100":[145],"person-months,":[146],"respectively)":[147],"did":[149],"not":[150],"significantly":[151],"differ":[152],"elderly":[154,182],"or":[156,165],"presence":[159],"cirrhosis,":[162],"worsening":[163],"fibrosis":[164],"HCC.":[166],"high":[170,231],"(98.5%)":[172],"subgroups":[175],"investigated":[176],"(\u226594%),":[177],"including":[178],"who":[180],"(98.2%),":[183],"treatment-experienced":[184],"(97.6%),":[185],"(\u226595.8%),":[188],"had":[189],"existing":[190],"NS5A":[191],"resistance-associated":[192],"substitutions":[193],"reported":[194],"pre-treatment":[195],"(95.0%),":[196],"cirrhosis":[198],"(95.7%),":[199],"HCC":[200],"(94.0%)":[201],"other":[203],"diseases":[206],"(96.1%).":[207],"In":[208],"this":[209],"large,":[210],"infection,":[220],"resulted":[223],"incidence":[226],"events,":[229],"effectiveness,":[233],"even":[234],"among":[235],"potentially":[238],"higher":[239],"risks":[240],"failure.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-09-08T00:00:00"}